COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00669994
Recruitment Status : Completed
First Posted : May 1, 2008
Last Update Posted : December 19, 2014
Information provided by (Responsible Party):

Brief Summary:
This trial evaluated how effective and safe Cipro XR was in treating female patients with signs and symptoms of a lower urinary tract infections. After 3 days of treatment, patients were evaluated to determine if signs/symptoms disappeared and the infecting bacteria was eliminated.

Condition or disease Intervention/treatment Phase
Urinary Tract Infection Drug: Ciprofloxacin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 180 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Open Label Non-comparative, Multi-center Trial to Evaluate the Efficacy and Safety of Cipro® XR 500 mg Once Daily for 3 Days in Treating Female Patients With Acute, Uncomplicated, Symptomatic Lower Urinary Tract Infections
Study Start Date : July 2003
Actual Study Completion Date : October 2003

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm 1 Drug: Ciprofloxacin
Cipro XR 500 mg tablets taken once daily

Primary Outcome Measures :
  1. Bacteriologic outcome in patients with UTI caused by S. saprophyticus [ Time Frame: 4-11 days post-treatment ]

Secondary Outcome Measures :
  1. Adverse Events Collection [ Time Frame: Up to 4-11 days post-treatment ]
  2. Clinical Response [ Time Frame: 4-11 days post-treatment ]
  3. Incidence of premature terminations [ Time Frame: Premature discontinuation ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 44 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Non-pregnant, non-lactating female outpatients between the ages of 18 - 44 years (inclusive)
  • Patients with at least two of the following clinical signs and symptoms of an uUTI:

    • Dysuria
    • Frequency
    • Urgency
    • Suprapubic pain
  • Patients with onset of symptoms < 72 hours prior to study entry
  • Patients with one positive pre-treatment clean-catch midstream urine culture at enrollment in the study, defined as > 10000 CFU/mL (study drug treatment is permitted prior to the availability of urine culture results)
  • Positive leukocyte esterase (LE) (1+ or greater) utilizing a urine dipstick method of analysis
  • Patients willing to give written informed consent
  • Cultures must be performed on pre-treatment clean-catch midstream urine (MSU) specimens

Exclusion Criteria:

  • Males
  • Women who are pregnant, nursing, or not using two medically accepted, effective methods of birth control
  • Patients with known or suspected hypersensitivity to quinolones
  • Patients unable to take oral medication for any reason
  • Patients with an asymptomatic bacteriuria
  • Patients with complicated UTI, defined as: a clinical syndrome characterized by the development of systemic and local signs and symptoms of fever (> 38.3°C/101°F orally), chills, malaise, flank pain, back pain, or costovertebral angle (CVA) pain or tenderness
  • Symptoms as outlined in the inclusion criteria occurring in the presence of a functional or anatomical abnormality of the urinary tract or in the presence of urinary catheterization
  • Patients with symptoms of a UTI within the 4 weeks prior to the present episode
  • Patients with the onset of symptoms >72 hours prior to study entry
  • Patients with three or more episodes of any UTI in the past 12 months
  • Patients with evidence of factors predisposing to the development of UTIs, including calculi, stricture, primary renal disease (e.g. polycystic renal disease), or neurogenic bladder
  • Patients who received systemic antimicrobial therapy within 48 hours prior to entry
  • Patients with a neutrophil count < 1000/mm3, CD4 < 200/mm3 or other conditions associated with significant depression in host defense; HIV testing is not mandatory
  • Patients requiring concomitant systemic antibacterial therapy with agents not specified in this protocol
  • Patients with a previous history of tendinopathy associated with fluoroquinolones
  • Patients diagnosed with a rapidly fatal underlying disease (death expected within six months)
  • Patients requiring concomitant use of theophylline
  • Patients previously enrolled in this clinical study
  • Patients taking an investigational drug in the last 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00669994

Layout table for location information
United States, Alabama
Birmingham, Alabama, United States, 35205
Birmingham, Alabama, United States, 35242
Pelham, Alabama, United States, 35124
United States, Arizona
Phoenix, Arizona, United States, 85023
United States, California
Laguna Hills, California, United States, 92653
Long Beach, California, United States, 90806
San Diego, California, United States, 92182-4701
San Luis Obispo, California, United States, 93401
San Mateo, California, United States, 94403-4398
Sylmar, California, United States, 91342
Yorba Linda, California, United States, 92886
United States, Connecticut
Avon, Connecticut, United States, 06001
United States, Florida
Clearwater, Florida, United States, 33761
Pembroke Pines, Florida, United States, 33024
United States, Indiana
Evansville, Indiana, United States, 47714
United States, Massachusetts
Milford, Massachusetts, United States, 01757
United States, Michigan
Royal Oak, Michigan, United States, 48073-6769
United States, New Jersey
Elizabeth, New Jersey, United States, 07202-3672
Holmdel, New Jersey, United States, 07733
United States, New York
Camillus, New York, United States, 13031
United States, Pennsylvania
Beaver, Pennsylvania, United States, 15009
Feasterville, Pennsylvania, United States, 19053
Hatboro, Pennsylvania, United States, 19040
United States, South Carolina
Summerville, South Carolina, United States, 29485
United States, Texas
San Antonio, Texas, United States, 78209
United States, Utah
Murray, Utah, United States, 84107
Salt Lake City, Utah, United States, 84102
Salt Lake City, Utah, United States, 84109
Salt Lake City, Utah, United States, 84121
West Jordan, Utah, United States, 84088
United States, Wisconsin
Madison, Wisconsin, United States, 53715
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer

Layout table for additonal information
Responsible Party: Bayer Identifier: NCT00669994    
Other Study ID Numbers: 100546
First Posted: May 1, 2008    Key Record Dates
Last Update Posted: December 19, 2014
Last Verified: December 2014
Keywords provided by Bayer:
Urinary Tract Infection
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Urinary Tract Infections
Urologic Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors